Nolan H. Sigal

The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin

F. Dumont, J. Siekierka, C. S. Lin, 1992, The Journal of experimental medicine.

FK-506 and cyclosporin A: selective inhibition of calcium ionophore-induced polymorphonuclear leukocyte degranulation.

N. Sigal, M. Forrest, G. Koo, 1991, Biochemical pharmacology.

FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes.

N. Sigal, R. Boltz, J. Siekierka, 1991, Cellular immunology.

Characterization of high molecular weight FK-506 binding activities reveals a novel FK-506-binding protein as well as a protein complex.

N. Sigal, R. Kincaid, M. Martin, 1992, The Journal of biological chemistry.

A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus.

N. Sigal, S. O'keefe, M. Martin, 1998, Transplantation.

The cytosolic-binding protein for the immunosuppressant FK-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase.

N. Sigal, H. Greulich, G. Wiederrecht, 1990, The Journal of biological chemistry.